Clinical Trial Update: Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin) [Phase 1]

View source ↗

Summary

Phase 1 subcutaneous study of BG00010 (Neublastin) evaluating single and multiple ascending doses has completed in adults with lumbar radiculopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lumbar Radiculopathy

Drugs mentioned

• Neublastin (BG00010)

Snippet

Sponsor: Biogen | Conditions: Painful Lumbar Radiculopathy, Healthy | Phase 1 | Status: COMPLETED